Subscribe to RSS
DOI: 10.1055/s-0044-1791959
Correlation of HPV-16, HPV-18 Genotypes with p16 Expression in Head and Neck Cancer: A Study from Western India
Abstract
Objectives This retrospective study aims to elucidate the clinical associations of HPV-16, HPV-18, and p16 expression with clinicopathological parameters, risk behaviors, and survival outcomes in head and neck cancer patients from the western Indian population.
Methods Clinical data of total 92 enrolled HNC patients diagnosed between years 2021 and 2023 were retrospectively collected from medical records. Formalin-fixed, paraffin-embedded blocks of all enrolled patients were collected whose p16 expression by immunohistochemistry tests were already performed. HPV-16 and HPV-18 infection was studied by real-time polymerase chain reaction. Associations between viral status, p16 expression, clinicopathological parameters, risk behaviors, and survival outcomes were assessed using SPSS statistical software version 20. p-Value ≤0.05 was considered to be statistically significant.
Results Among the 92 enrolled HNC patients, HPV-16 infection was detected in only 12 (13%) patients, with the remaining 80 (87%) testing negative. No HPV-18 infections were observed in any patient. Additionally, p16 expression was positive in only 13 (14%) patients, while 79 (86%) showed negative expression. A statistically significant correlation was found between metastasis involvement and positive HPV-16 infection (p < 0.001), with all HPV-16-positive cases exhibiting metastasis. A trend was also noted between the base of tongue and other clinical site subtypes with positive HPV-16 infection (p = 0.063). However, no other clinicopathological or risk behaviors showed significant associations with HPV-16 infection and p16 expression. Overall survival analysis revealed that neither HPV-16 infection nor p16 expression served as significant prognosticators in the HNC patient cohort (p > 0.05).
Conclusion This study provides comprehensive insights into the clinical relevance of HPV-16, HPV-18 infections, and p16 expression in HNC among the western Indian population. Understanding the associations between HPV-16, HPV-18, and p16 expression with clinicopathological parameters and survival outcomes may aid in optimizing patient management strategies, including personalized treatment approaches and targeted interventions. Further prospective studies are warranted to validate these findings and explore potential therapeutic implications.
Keywords
clinicopathological parameters - head and neck cancer - HPV-16 - HPV-18 - p16 expression - risk behaviors - survival outcomesSource of Support
The study was funded by The Gujarat Cancer and Research Institute and The Gujarat Cancer Society.
Publication History
Received: 17 June 2024
Accepted: 21 September 2024
Article published online:
18 November 2024
© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Sri S, Ramani P, Premkumar P, Ramshankar V, Ramasubramanian A, Krishnan RP. Prevalence of human papillomavirus (HPV) 16 and 18 in oral malignant and potentially malignant disorders: a polymerase chain reaction analysis–a comparative study. Ann Maxillofac Surg 2021; 11 (01) 6-11
- 2 Lydiatt WM, Patel SG, O'Sullivan B. et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67 (02) 122-137
- 3 Parshad S, Nandi S, Marwah N. et al. Human papillomavirus 16 and 18 in squamous cell carcinoma of oral cavity and sexual practices: a pilot study at a tertiary care hospital of North India. Natl J Maxillofac Surg 2015; 6 (02) 185-189
- 4 Patel KR, Vajaria BN, Begum R. et al. Prevalence of high-risk human papillomavirus type 16 and 18 in oral and cervical cancers in population from Gujarat, West India. J Oral Pathol Med 2014; 43 (04) 293-297
- 5 Ralli M, Singh S, Yadav SP, Sharma N, Verma R, Sen R. Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma. J Cancer Res Ther 2016; 12 (01) 232-237
- 6 de Abreu PM, Có ACG, Azevedo PL. et al. Frequency of HPV in oral cavity squamous cell carcinoma. BMC Cancer 2018; 18 (01) 324
- 7 Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002; 55 (01) 58-60
- 8 Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 2010; 5: 4
- 9 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363 (01) 24-35
- 10 Kühn JP, Schmid W, Körner S. et al. HPV status as prognostic biomarker in head and neck cancer—which method fits the best for outcome prediction?. Cancers (Basel) 2021; 13 (18) 4730
- 11 Hashmi AA, Younus N, Naz S. et al. p16 immunohistochemical expression in head and neck squamous cell carcinoma: association with prognostic parameters. Cureus 2020; 12 (06) e8601